4595-61-3

Basic information

• Product Name: 5-Pyrimidinecarboxylic acid
• Synonyms: 5-PYRIMIDINECARBOXYLIC ACID;AKOS 91242;RARECHEM AK ML 0570;PYRIMIDINE-5-CARBOXILIC ACID;PYRIMIDINE-5-CARBOXYLIC ACID;5-Pyrimidinecarboxylic acid (6CI,7CI,8CI,9CI);5-Carboxypyrimidine;Pyrimidine-5-carboxylic acid ,98%
• CAS NO: 4595-61-3
• Molecular Formula: C₅H₄N₂O₂
• Molecular Weight: 124.09746
• EINECS: 224-994-2
• Product Categories: PYRIMIDINE;pharmacetical;Pyrimidines;Building Blocks;Heterocycle-Pyrimidine series
• Mol File: 4595-61-3.mol
• Article Data: 7

Chemical Properties

• Melting Point: 259 °C
• Boiling Point: 318.7 °C at 760 mmHg
• Flash Point: 146.5 °C
• Appearance: /Solid
• Density: 1.403 g/cm³
• Vapor Pressure: 0.000148mmHg at 25°C
• Refractive Index: 1.578
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.74±0.10(Predicted)
• CAS DataBase Reference: 5-Pyrimidinecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Pyrimidinecarboxylic acid(4595-61-3)
• EPA Substance Registry System: 5-Pyrimidinecarboxylic acid(4595-61-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-36
• Safety Statements: 22-26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 4595-61-3(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white solid

Uses

Pyrimidine-5-carboxylic Acid is used in the preparation of heterocyclic compounds as an antiviral agent.

InChI:InChI=1/C5H4N2O2/c8-5(9)4-1-6-3-7-2-4/h1-3H,(H,8,9)

Upstream product

• 2036-41-1 5-methylpyrimidine 
• 51940-64-8 ethyl 2,4-dichloropyrimidine-5-carboxylate 
• 51957-32-5 4-chloro-5-methyl-pyrimidine 
• 28485-17-8 5-carbethoxyuracil 
• 17758-52-0 5-methyl-4(3H)-pyrimidinone 
• 40929-50-8 ethyl pyrimidine-5-carboxylate 
• 34253-01-5 pyrimidine-5-carboxylic acid methyl ester 
• 60-29-7 diethyl ether 
• 623-11-0 1-methyl-4-nitrosobenzene 
• 4595-59-9 5-bromopyrimidine 
• 124-38-9 carbon dioxide 

Downstream Products

• 40929-48-4 pyrimidine-5-carbonyl chloride 
• 1126633-21-3 Pyrimidine-5-carboxylic acid-{1-[4-(4-chloro-2-fluoro-phenoxy)-3-fluoro-benzylcarbamoyl]-cyclopropyl}-amide hydrochloride 
• 1126630-90-7 pyrimidine-5-carboxylic acid {1-[3-fluoro-4-(4-methoxy-phenoxy)-benzylcarbamoyl]-cyclopropyl}-amide 
• 1126631-57-9 pyrimidine-5-carboxylic acid {1-[2-chloro-4-(2-chloro-phenoxy)-benzyl-carbamoyl]-cyclopropyl}-amide 
• 1126631-61-5 pyrimidine-5-carboxylic acid {1-[4-(4-bromo-2-chloro-phenoxy)-benzylcarbamoyl]-cyclopropyl}-amide 
• 409357-05-7 pyrimidine-5-carboxylic acid hydrochloride 
• 40929-49-5 pyrimidine-5-carboxamide 
• 845830-01-5 N-[1-({[(3,3'-difluoro-2'-hydroxy-1,1'-biphenyl-4-yl)methyl]amino}carbonyl)cyclopropyl]pyrimidine-5-carboxamide 
• 845830-00-4 N-[1-({[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]amino}carbonyl)cyclopropyl]pyrimidine-5-carboxamide 
• 578767-41-6 N-[1-({[(3,3'-difluoro-2'-methoxy-1,1'-biphenyl-4-yl)methyl]amino}-carbonyl)cyclopropyl]pyrimidine-5-carboxamide 
• 1428926-29-7 N-[4-[[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl] methylene]cyclohexyl] pyrimidine-5-carboxamide 

Relevant articles and documents

Synthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABAA receptor agonists

A series of 6-aminonicotinic acid analogues have been synthesized and pharmacologically characterized at native and selected recombinant GABA A receptors. 6-Aminonicotinic acid (3) as well as 2- and 4-alkylated analogues (9-11, 14-16) display low to mid-micromolar GABAAR binding affinities to native GABAA receptors (Ki 1.1-24 μM). The tetrahydropyridine analogue of 3 (22) shows low-nanomolar affinity (K i 0.044 μM) and equipotency as an agonist to GABA itself as well as the standard GABAA agonist isoguvacine. Cavities surrounding the core of the GABA binding pocket were predicted by molecular interaction field calculations and docking studies in a α1β 2γ2 GABAA receptor homology model, and were confirmed by affinities of substituted analogues of 3. The tight steric requirements observed for the remarkably few GABAAR agonists reported to date is challenged by our findings. New openings for agonist design are proposed which potentially could facilitate the exploration of different pharmacological profiles within the GABAAR area.

THIAZOLYL-DIHYDRO-INDAZOLE

Disclosed are compounds of general formula (I), wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.

Quinolones as gonadotropin releasing hormone (GnRH) antagonists: Simultaneous optimization of the C(3)-aryl and C(6)-substituents

A series of 3-arylquinolones was prepared and evaluated for their ability to act as gonadotropin releasing hormone (GnRH) antagonists. A variety of substitution patterns of the 3-aryl substituent are described. The 3,4,5-trimethylphenyl substituent (23h) was found to be optimal. (C) 2000 Elsevier Science Ltd. All rights reserved.